Search clinical trials for: Atezolizumab Placebo

Total 54237 results

Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

France, United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Milan; IFOM, The FIRC Institute of Molecular Oncology

Not yet recruiting

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction (FASTIMMUNE)

Small Cell Lung Carcinoma

Italy
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Completed

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States, Korea, Republic of, Australia, Canada, Germany, Singapore
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Small-cell Lung Cancer | Neoadjuvant Therapy

China
Alain Algazi
Genentech, Inc.

Recruiting

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Carcinoma | Cancer | Head and Neck Cancer | Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Institut fuer Frauengesundheit
Samsung Bioepis Co., Ltd.

Recruiting

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON)

Breast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Female

Germany
University of Hawaii
Genentech, Inc.; Dendreon

Completed

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
PharmEvo Pvt Ltd

Completed

Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (HEATS)

Hepatitis C, Chronic

Pakistan
Bristol-Myers Squibb

Completed

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Hepatitis C

United States
Hoffmann-La Roche

Completed

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

Urothelial Carcinoma

Spain, United States, Korea, Republic of, Canada, United Kingdom, Czechia, Australia, Belgium, Brazil, China, Estonia, Finland, Greece, Hong Kong, Italy, Poland, Portugal, Slovenia, Mexico, Georgia, Russian Federation, Singapore, Th... and more
Centre Georges Francois Leclerc

Recruiting

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)

Metastatic Renal Cell Carcinoma | Metastatic Non Small Cell Lung Cancer | Metastatic Head and Neck Cancer | Metastatic Bladder Cancer

France
Fundacion para la Investigacion Biomedica del Hospital...

Recruiting

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Lung Cancer

Spain
Nilogen Oncosystems
Henry Ford Health System

Unknown

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL)

Non Small Cell Lung Cancer

United States
Genentech, Inc.

Completed

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, Korea, Republic of, Spain, France
Hoffmann-La Roche

Completed

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (IMpower133)

Small Cell Lung Carcinoma

Korea, Republic of, United States, Hungary, Poland, China, France, Greece, Spain, United Kingdom, Brazil, Italy, Germany, Mexico, Australia, Serbia, Russian Federation, Japan, Austria, Chile, Czechia, Taiwan
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (ATREZZO)

Breast Cancer

Spain
AGO Research GmbH
Hoffmann-La Roche

Active, not recruiting

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Recurrent Ovarian Carcinoma

Norway, Spain, France, Switzerland, Denmark, Germany, Sweden, Belgium, Finland, Austria, Estonia, Lithuania
Hoffmann-La Roche

Withdrawn

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States
Hoffmann-La Roche

Completed

A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Breast Cancer

Canada, Spain, France, United Kingdom, Italy
Hoffmann-La Roche

Terminated

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Bladder Cancer

United States
Spanish Oncology Genito-Urinary Group
Roche Pharma AG

Completed

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma (AUREA)

Locally Advanced or Metastatic Urothelial Carcinoma

Spain
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
CHA University
Boryung Pharmaceutical Co., Ltd

Recruiting

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab (HCC)

Advanced Hepatocellular Carcinoma

Korea, Republic of
Consorzio Oncotech

Active, not recruiting

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Metastatic Breast Cancer | Triple Negative Breast Cancer | PD-L1 Gene Mutation

Italy
Hoffmann-La Roche

Active, not recruiting

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

Triple Negative Breast Neoplasms

Korea, Republic of, Italy, China, Finland, France, Hungary, Spain, United Kingdom, Argentina, United States, Bosnia and Herzegovina, Brazil, Chile, Germany, Poland, Russian Federation, Peru, Morocco, Mexico, Portugal, Serbia, Turkey, South Africa and more
The Netherlands Cancer Institute
Roche Pharma AG; Borstkanker Onderzoek Groep

Active, not recruiting

Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer (Triple-B)

Breast Cancer

Netherlands
Replimune Inc.
Roche Pharma AG

Active, not recruiting

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

MSS | pMMR | Refractory Metastatic Colorectal Cancer

United States
Abramson Cancer Center at Penn Medicine

Recruiting

SBRT With Atezo/Bev for HCC

Hepatocellular Carcinoma

United States
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
Hoffmann-La Roche

Completed

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Lymphoma

United States, France, Germany, Italy, United Kingdom
TransThera Sciences (Nanjing), Inc.

Recruiting

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Gastric Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Small-cell Lung Cancer | Thyroid Cancer | Biliary Tract Cancer | Gallbladder Cancer | HER2-negative Breast Cancer

China
University Hospital, Montpellier

Recruiting

Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial (AB-LATE02)

Hepatocellular Carcinoma

France
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Fundación GECP

Active, not recruiting

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

Non Small Cell Lung Cancer

Spain
Kristoffer Rohrberg

Recruiting

Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy (TEMPLE)

Metastatic Cancer | Solid Tumor, Adult

Denmark
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche

Recruiting

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)

Breast Cancer

France
University Hospital, Ghent
Jules Bordet Institute; AZ Sint-Lucas Gent; GZA Ziekenhuizen Campus Sint-Augustinus and other collaborators

Completed

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (CHEERS)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma

Belgium
Medical University of Vienna

Recruiting

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Hepatocellular Carcinoma

Austria
National Taiwan University Hospital

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

NSCLC Stage IIIB~IV

Taiwan
University of Rochester

Withdrawn

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Cancer of Liver

United States
Genentech, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
MTI University

Unknown

The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy

Egyptian Patients, HCV Treatment, Kidney Function

Egypt
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
Genentech, Inc.

Completed

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Non-Small Cell Lung Cancer

United States

Search clinical trials for: Atezolizumab Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations